Business Context and Reporting Period
This Form 6-K filing by ProQR Therapeutics N.V. covers the month of July 2021. The report details corporate governance changes approved by shareholders at the 2021 Annual General Meeting held on May 19, 2021, which became effective on June 10, 2021.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on amendments to the Articles of Association and does not contain financial performance data.
Material Changes
The filing reports two material amendments to the Company's Articles of Association:
- First Amendment: Combined the existing compensation committee and nominating and corporate governance committee into a single "compensation, nominating and corporate governance committee" and established a new research and development committee.
- Second Amendment: Increased the authorized share capital for ordinary shares from 90,000,000 to 170,000,000 ordinary shares. The additional shares possess rights identical to currently outstanding ordinary shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document serves as a formal notice of the executed notarial deeds regarding the Articles of Association.
Key Facts for Investor Verification
- Shareholders approved the restructuring of board committees and the creation of a new R&D committee.
- Authorized share capital was increased by 80,000,000 shares (from 90M to 170M).
- The amendments became effective on June 10, 2021.
- The full text of the Amended Articles of Association is attached as Exhibit 1.1.